Build status - In Progress

PET/CT imaging as a measure of response in patients with advanced melanoma on immunotherapy plus hydroxychloroquine.

PET/CT imaging as a measure of response in patients with advanced melanoma on immunotherapy plus hydroxychloroquine.
Recruiting
18 years - 99 years
All
Phase N/A
20 participants needed
1 Location

Brief description of study

The research study is a companion trial to the LIMIT Melanoma Trial, This study is being conducted to test a new investigational imaging agent called 89Zr-Df-IAB22M2C with positron emission tomography/computed tomography (PET/CT) scans on participants with advanced melanoma who are participating in the LIMIT Melanoma Trial. The imaging agent could help the doctor see where your CD8 T cells are located, which may help patients to determine likely response to treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: melanoma
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, Age 18 or older History of histologically confirmed melanoma as assessed per medical record review

Updated on 04 Aug 2024. Study ID: 844867

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center